Compounded Semaglutide vs Wegovy 2026

See if you qualify — start your assessment →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3-month and 6-month plans · cancel anytime

At a glance: side-by-side comparison

	Wegovy® (brand-name)	Compounded semaglutide
FDA-approved?	Yes (for chronic weight management)	No — not FDA-approved
Active ingredient	Semaglutide	Semaglutide (base form)
Manufacturer / maker	Novo Nordisk	State-licensed 503A compounding pharmacy
List price / month	~$1,349 (as of June 2026)	—
Self-pay / typical price	~$349/mo (NovoCare program)	~$99–$250/mo (telehealth programs)
Studied in clinical trials?	Yes (STEP program; STEP-1, -2, -3, -5)	No — not studied in efficacy trials
Therapeutically equivalent to Wegovy?	Yes, it IS Wegovy	No — not therapeutically equivalent
Dosing form	Pre-filled auto-injector pens (0.25 mg–2.4 mg)	Vials; dose set by prescribing clinician
Boxed warning	Thyroid C-cell tumors (class effect)	Thyroid C-cell tumors (same class)
Insurance coverage possible?	Yes, with qualifying diagnosis + prior auth	Generally no

Prices as of June 2026; verify directly with manufacturers and telehealth providers before deciding. Trial data refers to studies of the FDA-approved branded medications, not compounded versions.

Same active ingredient — but not the same product

Both Wegovy® and compounded semaglutide contain semaglutide as the active ingredient — a GLP-1 receptor agonist that suppresses appetite and slows gastric emptying. But sharing an active ingredient does not make two preparations the same product. The comparison most often misses what differs:

• Manufacturing standards: Wegovy is produced under FDA's Current Good Manufacturing Practice (cGMP) regulations, which govern purity, potency, sterility, and consistency at commercial scale. A compounded preparation is made in a licensed pharmacy to fill one prescription at a time; it is not subject to the same pre-market testing process.
• Regulatory approval: The FDA reviewed Wegovy's clinical trial data, manufacturing process, and labeling before approving it. Compounded semaglutide has not gone through that process — it is not FDA-approved, and the FDA has not independently verified its safety, effectiveness, or quality.
• Therapeutic equivalence: The FDA's concept of therapeutic equivalence applies to approved drugs with an established bioequivalence standard. There is no generic semaglutide; calling compounded semaglutide a "generic Wegovy" or implying it produces the same outcomes is factually incorrect and has been specifically cited in FDA warning letters to telehealth companies.
• Formulation details: Some compounded versions have used non-base forms of semaglutide (such as semaglutide sodium or acetate salts) that are not present in Wegovy's approved formulation. The FDA has raised specific concerns about these variant forms.

The honest summary: same molecule at the core, but the two preparations are regulated differently, have different levels of evidence, and should not be treated as interchangeable.

The cost picture: Wegovy vs compounded semaglutide (2026)

Cost is the most common reason patients ask this question, and the honest comparison has gotten more nuanced since 2023. Here is where prices stood as of June 2026 — verify directly before making a decision, since prices change frequently.

Wegovy's pricing tiers

• List price: approximately $1,349/month without insurance — the price if you pay a pharmacy's full cash rate (NovoCare, as of June 2026).
• NovoCare self-pay program: Novo Nordisk now offers Wegovy directly to uninsured or under-insured patients at approximately $349/month through its NovoCare program. This has narrowed the cost gap considerably since 2023.
• With commercial insurance: Wegovy may be covered with a qualifying diagnosis (obesity, BMI ≥30, or BMI ≥27 with a weight-related comorbidity) and prior authorization. Out-of-pocket costs vary widely by plan. See our guide to does insurance cover Wegovy and Zepbound and how to get GLP-1 coverage.

Compounded semaglutide pricing

Telehealth programs offering compounded semaglutide typically price it between $99 and $250/month, depending on the platform, dose, and what's included. The pricing range reflects real variation: some programs charge for the medication only; others bundle physician oversight, ongoing check-ins, and behavioral support into one price. For an up-to-date comparison of telehealth GLP-1 pricing, see the GLP-1 telehealth pricing dataset (2026) and our comprehensive GLP-1 cost guide.

The fair comparison today is self-pay Wegovy (~$349/mo) vs compounded telehealth — not Wegovy's list price. The gap is real, but smaller than the headlines from 2022–2023 suggest. Weigh what is included in each: a branded pen with a pharmacist vs a vial, a prescription, clinical oversight, and a support program. For a deeper breakdown of the cost drivers, see our article on compounded vs brand GLP-1 cost.

What FDA approval actually means — and why it matters

FDA approval is not a bureaucratic formality. Before Novo Nordisk could sell Wegovy, it had to demonstrate — through large, randomized, placebo-controlled trials — that the drug was safe and effective for its intended use. The FDA reviewed that data, inspected manufacturing facilities, and approved the specific formulation, dosage regimen, and labeling.

For compounded semaglutide, none of that pre-market review happened. That does not mean it is necessarily ineffective or unsafe — compounding is a long-established pharmacy practice — but it does mean:

• No independent body has verified the potency, purity, or sterility of any specific compounded batch.
• There is no pre-established evidence base for the compounded product's efficacy.
• The FDA's post-market pharmacovigilance system (which tracks adverse events for approved drugs) does not cover compounded versions in the same way.

The FDA has explained its compounding policy framework in detail at fda.gov/drugs/human-drug-compounding and has published patient-specific safety information at fda.gov — postmarket drug safety. Both are worth reading before a clinical conversation about compounded GLP-1s.

What the clinical trials actually measured

When you see the figure "about 14.9% average body weight loss," that is a result from the STEP-1 trial (Wilding et al., NEJM, 2021) — a randomized, placebo-controlled study of the FDA-approved branded drug, Wegovy, at its approved dose (2.4 mg once weekly), in adults with obesity or overweight with at least one weight-related condition, over 68 weeks. That result belongs to Wegovy in that study population. It does not transfer to compounded semaglutide.

Similarly, the SELECT trial (Lincoff et al., NEJM, 2023) — which found a significant reduction in major adverse cardiovascular events with semaglutide 2.4 mg — was a study of the branded Wegovy in adults with established cardiovascular disease and overweight or obesity, not diabetes. Those cardiovascular findings apply to the approved product in that study population.

For context on how semaglutide compares to tirzepatide (the active ingredient in Zepbound® and Mounjaro®), the SURMOUNT-5 head-to-head trial (NEJM, 2025) compared the two branded molecules head-to-head. Both studies involve FDA-approved branded drugs — not compounded versions.

Compounded semaglutide has not been studied in large randomized controlled trials for weight loss. Any provider or platform that presents Wegovy's or Ozempic's trial results as expected outcomes for their compounded product is misrepresenting the evidence. Individual results from any GLP-1 therapy vary, and realistic expectations require a conversation with a licensed clinician. The NIDDK's overview of prescription weight-loss medications provides a solid starting frame for understanding the category.

Safety, quality, and legality in 2026

The legal and regulatory backdrop for compounded semaglutide shifted significantly in 2025 and is still evolving. A few facts that are important to understand before making a clinical decision:

The shortage exception no longer applies broadly

From approximately 2022 through early 2025, the FDA placed semaglutide on its drug shortage list, which allowed 503A compounding pharmacies to legally prepare compounded versions for patients who could not access the branded drug. The FDA declared that shortage resolved in February 2025. With the shortage designation lifted, the broad compounding exception that underpinned much of the mass-market telehealth compounded-GLP-1 industry no longer applies. Today, compounded semaglutide should be a genuinely patient-specific preparation — for a patient with a documented clinical need that the branded product cannot meet — not an off-the-shelf substitute. The FDA has been explicit about this, and several telehealth companies received warning letters in 2025 for continuing to market compounded GLP-1s as interchangeable with or superior to the branded drugs. See the FDA's statement on GLP-1 compounding policy.

503A vs 503B pharmacies

Most compounded semaglutide reaching individual patients comes from 503A pharmacies — state-licensed pharmacies that compound based on individual prescriptions. 503B outsourcing facilities operate under closer FDA oversight and can compound larger quantities, but are subject to their own constraints on what they may compound. If a telehealth provider offers compounded semaglutide, confirm which type of pharmacy is dispensing it and that the pharmacy is licensed in your state.

Counterfeit and unregulated products

The FDA has specifically warned patients and providers about counterfeit and unregulated GLP-1 products that are marketed online as "semaglutide" but may not contain the correct molecule or dose. See the FDA's advisory on unapproved compounded GLP-1 drugs. Using a provider that names a specific licensed pharmacy — and can verify its licensure — is the minimum due diligence.

Who is compounded semaglutide prescribed for?

Even within the current legal framework, compounded semaglutide can be appropriately prescribed in patient-specific situations. Common legitimate scenarios include:

• A patient who needs a dose or formulation that the branded product does not offer at a commercially available strength.
• A patient with a documented allergy or sensitivity to an inactive ingredient in the branded formulation.
• A patient for whom the branded product is not accessible due to cost, and who, after a clinical conversation, proceeds under a clinician's judgment that compounded therapy is appropriate for their specific situation.

In all cases, the decision should involve a U.S.-licensed physician reviewing the patient's complete health history — not an automated questionnaire that approves everyone. The FDA's position, reinforced after the 2025 warning letters, is that compounded GLP-1s should not be marketed or prescribed as a mass-market substitute for the approved branded drugs.

FSA and HSA reimbursement

Compounded GLP-1 medications may be eligible for reimbursement through a Flexible Spending Account (FSA) or Health Savings Account (HSA) under Internal Revenue Code Section 213(d), which covers prescription medications obtained from licensed medical providers. Eligibility depends on your specific plan administrator and, in some cases, may require a letter of medical necessity from your prescribing clinician.

Important qualifications: this is a reimbursement-only pathway — neither Nouri nor the dispensing pharmacy can directly bill your FSA or HSA card. Whether a given expenditure qualifies is determined by your plan administrator, not your provider. Before submitting a claim, confirm eligibility with your plan administrator. For more detail, see our guide to FSA and HSA for GLP-1 medications.

Related comparisons

• Compounded Tirzepatide vs Zepbound: Cost & Differences (2026)
• Brand-Name vs Compounded GLP-1: Full Comparison
• Ozempic vs Wegovy: What's the Difference?
• Wegovy Cost Without Insurance (2026)
• GLP-1 Costs in 2026: Full Pricing Guide

Where Nouri fits

If you and a licensed clinician decide a compounded GLP-1 is clinically appropriate for you, Nouri offers compounded semaglutide or compounded tirzepatide as part of one complete program — The Program — which includes the compounded medication (when prescribed), a personalized nutrition plan, a movement plan, and ongoing clinician oversight, at one all-inclusive price. Any dose is the same price.

Compounded semaglutide starts at $120/month on the 6-month plan ($720 billed every 6 months) or $145/month on the 3-month plan ($435 billed every 3 months). Compounded tirzepatide starts at $175/month on the 6-month plan ($1,050 billed every 6 months) or $199/month on the 3-month plan ($597 billed every 3 months). The program is available in all 50 U.S. states; Nouri is LegitScript-certified.

Your medication is prepared by a named, state-licensed 503A compounding pharmacy — Jungle Jim's Pharmacy (Fairfield, OH) or VialsRX — and ships free and discreetly to your door. Your intake is reviewed by a U.S.-licensed physician before any prescription is issued; not all applicants qualify. Compounded semaglutide contains the same active ingredient as Wegovy® and Ozempic®, but it is not FDA-approved and is not the same as, or therapeutically equivalent to, those products.

The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Start your 5-minute assessment →
Reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3-month and 6-month plans · cancel anytime

Frequently asked questions

Is compounded semaglutide the same as Wegovy?

No. They share the same active ingredient — semaglutide — but compounded semaglutide is not FDA-approved, was not studied in Wegovy's clinical trials, and is not therapeutically equivalent to Wegovy. There is no generic version of Wegovy. The FDA has specifically warned against marketing compounded semaglutide as equivalent to the branded product.

Is compounded semaglutide as effective as Wegovy?

No one can responsibly claim that. Wegovy's headline result — approximately 14.9% average body weight loss at 68 weeks in the STEP-1 trial — comes from clinical research on the FDA-approved branded product. Compounded semaglutide has not been studied in its own efficacy trials; its outcomes are not established. Individual results from any GLP-1 therapy vary. Discuss realistic expectations with a licensed clinician.

Is compounded semaglutide less expensive than Wegovy?

Generally yes, on sticker price. Compounded semaglutide via telehealth typically runs $99–$250/month, versus Wegovy's approximately $349/month through Novo Nordisk's self-pay NovoCare program (or approximately $1,349 list price), as of June 2026. The gap is real but narrower than it was when only the $1,349 list price was widely available. Prices change frequently; verify current figures before deciding. See the 2026 GLP-1 cost guide for a broader breakdown.

Why is compounded semaglutide less expensive?

Compounded semaglutide is not manufactured at commercial scale, FDA-approved, or marketed like a brand-name drug — it is prepared by a compounding pharmacy to fill an individual prescription. That different production and distribution path means it does not carry the costs of large-scale manufacturing, clinical trial programs, FDA approval processes, or brand-name marketing. The tradeoff is the absence of pre-market efficacy and safety review by the FDA.

Is compounded semaglutide the same as Ozempic?

No. Ozempic® is a brand-name semaglutide product made by Novo Nordisk — FDA-approved for type 2 diabetes management at doses up to 2 mg. Wegovy® is the same molecule at a higher dose (2.4 mg) with FDA approval for chronic weight management. Compounded semaglutide shares the same active ingredient as both branded products but is not FDA-approved, was not studied in their clinical trials, and is not the same as or equivalent to either brand.

Is compounded semaglutide safe and legal in 2026?

When prepared by a state-licensed 503A pharmacy from a valid individual prescription, compounding is a long-established, legitimate practice. However, compounded drugs are not FDA-approved or FDA-evaluated for safety, effectiveness, or quality. The FDA has warned about counterfeit and unregulated compounded GLP-1 products sold online. Since the semaglutide shortage was declared resolved in February 2025, the compounding landscape has tightened further — compounding is appropriate only in genuinely patient-specific situations. Always confirm that your provider names a specific licensed pharmacy and uses a licensed prescribing clinician for your individual case.

Sources & references

1. STEP-1 trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH et al., NEJM, 2021. (Tier 1 — primary clinical trial of the FDA-approved branded drug Wegovy)
2. SELECT trial — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff AM et al., NEJM, 2023. (Tier 1 — cardiovascular outcomes trial of branded Wegovy 2.4 mg)
3. SURMOUNT-1 trial — Tirzepatide for Obesity. Jastreboff AM et al., NEJM, 2022. (Tier 1 — primary trial of FDA-approved branded tirzepatide)
4. SURMOUNT-5 — Tirzepatide vs. Semaglutide, head-to-head. NEJM, 2025. (Tier 1 — direct comparison of branded molecules)
5. FDA: Human Drug Compounding — policy, Q&A, and oversight framework. (Tier 1 — FDA .gov)
6. FDA: Concerns About Unapproved GLP-1 Drugs Used for Weight Loss. (Tier 1 — FDA .gov)
7. FDA: Clarification of Policies for Compounders as GLP-1 Supply Stabilizes. (Tier 1 — FDA .gov)
8. FDA: Postmarket Drug Safety Information for Patients and Providers. (Tier 1 — FDA .gov)
9. NIDDK: Prescription Medications to Treat Overweight and Obesity. (Tier 1 — NIH .gov)
10. Novo Nordisk / NovoCare: Wegovy Self-Pay Pricing (June 2026). (Tier 3 — manufacturer, dated)
11. GLP-1 Telehealth Pricing Dataset 2026 — Nouri (original compiled data, June 2026).

Medically reviewed by Amber Patel, MD, medical reviewer, Nouri Editorial Team. Nouri content is reviewed by licensed clinicians and updated as guidance changes. Last reviewed June 29, 2026.

This article is for general educational purposes only — it is not medical advice. Talk to a licensed clinician about what is right for you. Ozempic®, Wegovy® and Rybelsus® (semaglutide) are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® (tirzepatide) are registered trademarks of Eli Lilly and Company; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Clinical-trial results described in this article are from studies of the FDA-approved branded medications in their specific trial populations; compounded semaglutide was not studied in these trials, is not FDA-approved, and is not the same as or therapeutically equivalent to the brand-name drugs. Results from any GLP-1 therapy vary between individuals and are not guaranteed. GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); other risks include pancreatitis, gallbladder disease, and acute kidney injury; they are not for use during pregnancy. Compounded semaglutide may be eligible for FSA/HSA reimbursement under IRC §213(d) — confirm eligibility with your plan administrator; reimbursement is not guaranteed. Prices are as of June 2026 and change frequently; verify directly with providers before deciding.